Mironid raises a £34m Series B including £8.4m from Scottish National Investment Bank to advance small molecule treatments for kidney diseases

Mironid is a Glasgow-based biopharmaceutical company developing small molecule therapeutics for Autosomal Dominant Polycystic Kidney Disease, a life-threatening hereditary kidney disease with limited treatment options. Its first-in-class LoAc drug candidates target the abnormally high kidney cAMP levels that drive the uncontrolled growth of fluid-filled cysts.